Fig. 6: Effects of TLR4 inhibitor on IECs proliferation, differentiation and intestinal barrier.
a The representative small intestine images in rats treated with saline (control) or TLR4 inhibitor (TAK-242). Scale bar 5 cm, n = 8. b HE staining images of small intestine in rats treated with saline (control) or TLR4 inhibitor (TAK-242). Scale bar 100 μm, n = 4. c Measurement of small intestine length (n = 8), villus height and crypt depth (n = 4) in rats treated with saline (control) or TLR4 inhibitor (TAK-242). Two-way ANOVA was used; interaction p < 0.0001. d Immunohistochemical staining images of Ki67 in the small intestine, and the quantification of Ki67 positive cells in the crypts (determined based on the number of brown-stained cell nuclei in the crypts). Scale bar 100 μm, n = 4. Two-way ANOVA was used; interaction p < 0.05. e Images and quantification of goblet cells stained with AB-PAS in the small intestine. Scale bar 100 μm, n = 4. Two-way ANOVA was used; interaction p < 0.01. f Images and quantification of immunohistochemical staining for lysozyme in the crypt. Scale bar 100 μm, n = 4. Two-way ANOVA was used; interaction p < 0.01. g Western blot analysis for MUC2, Villin, ZO-1 and E-cadherin protein levels in the small intestine of WT, LRRK2R1627P and LRRK2−/− rats treated with saline (control) or TLR4 inhibitor (TAK-242), n = 4. One-way ANOVA was used. Data are presented as mean ± SEM, *p < 0.05, **p < 0.01.
